The IPKat

OCTOBER 3, 2022

October 26, 2022 | Bird & Bird | "Webinar: The DSM Directive one year on (part II) Article 15: A power shift back to the publishers?" | online Article 15 of Directive 2019/790 builds on and follows a number of national initiatives aimed at remedying declining revenues in the press sector. Further information is available here.

Registration 62

Registration Intellectual Property IP Copyright 62

Trading Secrets

JUNE 3, 2022

This blog post summarizes some of the significant decisions grouped by the hot topics below. 2020 IL App (1st) 191790, the state appellate court affirmed the award of attorneys’ fees incurred by defendants under the bad faith fee shifting provision of the Illinois trade secrets statute. In Oakwood Lab’ys LLC v.

Law 59

Law Confidentiality Designs Design 59

The IPKat

DECEMBER 22, 2023

G2/21 and the mysteries of plausibility The topic that this Kat has spent the most electronic ink on this year is undoubtedly G 2/21. This Kat suspects that the shift to "credibility" is partly an attempt by the EPO to distance itself from the UK courts and their approach to plausibility as almost a legal concept in and of itself.

Invention 110

Invention Inventor Patent Law 110

Trading Secrets

DECEMBER 21, 2021

TUTSA provides similar monetary relief to both DTSA and UTSA, including actual losses, unjust enrichment, reasonable royalties, exemplary damages, and attorneys’ fees, under specific circumstances. Anatomy of an M&A Transaction: How to Issue Spot for Non-Compete, Trade Secrets/Confidential Information, and Intellectual Capital Concerns.

Confidentiality 69

Confidentiality Law Contracts Business 69

LexBlog IP

DECEMBER 21, 2021

TUTSA provides similar monetary relief to both DTSA and UTSA, including actual losses, unjust enrichment, reasonable royalties, exemplary damages, and attorneys’ fees, under specific circumstances. Anatomy of an M&A Transaction: How to Issue Spot for Non-Compete, Trade Secrets/Confidential Information, and Intellectual Capital Concerns.

Confidentiality 52

Confidentiality Law Contracts Business 52

Fish & Richardson Trademark & Copyright Thoughts

DECEMBER 2, 2020

For more information about any topic herein, please see our October 20, 2020 webinar, “ IP and Cannabis: The Current Landscape ,” or contact your Fish attorney. FDA Regulation. Until 2018, cannabis in almost all of its forms was regulated as a Schedule I controlled substance – the same category used for heroin and LSD.

IP 52

IP Registration Trademark Branding 52

Technology & Marketing Law Blog

JUNE 20, 2023

Condé Nast paid AWF $10,000 for a license to reproduce Orange Prince on the cover of the “Special Commemorative Issue.” “Goldsmith received neither a fee nor a source credit.” [Slip op. Barton Beebe’s empirical work on this topic. When the publishers learned of the Prince Series, they decided to use Orange Prince instead.

Fair Use 95

Fair Use Derivative Work Blogging Licensing 95

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 7, 2022

In Toshiba , the initial panel denied institution, finding the petition to be time-barred based on the USPTO not receiving the wire-transferred filing fee until Dec. Denials of institution – particularly the extent to which they are reviewable – have long been a contentious topic for the PTAB. Board Shifts between § 102 and § 103.

Reporting 52

Reporting Art Invention Patent 52

Trading Secrets

DECEMBER 29, 2022

TUTSA provides similar monetary relief to both DTSA and UTSA, including actual losses, unjust enrichment, reasonable royalties, exemplary damages, and attorneys’ fees, under specific circumstances. Employers should be particularly mindful of fee-shifting provisions (or other financial penalties) and choice of law/forum selection requirements.

Confidentiality 59

Confidentiality Business Law Contracts 59

LexBlog IP

DECEMBER 29, 2022

TUTSA provides similar monetary relief to both DTSA and UTSA, including actual losses, unjust enrichment, reasonable royalties, exemplary damages, and attorneys’ fees, under specific circumstances. Penalties, fee shifting provisions, and putative employee class actions add to risks that employers face.

Confidentiality 40

Confidentiality Business Law Contracts 40

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

The continued slow pace of approvals is potentially the result of the COVID-19 pandemic and related delays in clinical trials and facility inspections by FDA, as well as a re-prioritization and shifting of agency resources towards COVID-19 vaccines and treatments. The court entered the order of dismissal on September 8, 2021.

Litigation 52

Litigation Settlement Patent Marketing 52